MLAB Biosciences Appoints Dr. Edward Kaye as New Scientific Advisory Chair

MLAB Biosciences Strengthens Leadership with New Scientific Advisory Chair

MLAB Biosciences, a forward-thinking biotechnology firm dedicated to developing innovative therapies for neuromuscular diseases, announces the appointment of Dr. Edward M. Kaye as the Chair of its Scientific Advisory Board (SAB). This strategic move underscores MLAB's commitment to enhancing its scientific foundation as the company accelerates its developmental initiatives. Dr. Kaye, a recognized figure in the field, previously served as CEO for both Sarepta Therapeutics and Stoke Therapeutics, where he significantly contributed to the advancement of therapies for conditions such as Duchenne muscular dystrophy (DMD). His leadership is expected to fortify MLAB's efforts in navigating the complex landscape of drug development, as the company seeks to establish a top-tier advisory board.

Dr. Kaye’s extensive experience with DMD drug development is particularly relevant to MLAB's objectives. During his tenure at Sarepta, he played a pivotal role in the approval of Exondys 51, the first treatment designed to modify the course of DMD. His insights and proven track record in bringing therapies to fruition will provide invaluable guidance as MLAB focuses on its lead program, MLAB-001. This innovative muscle-specific antibody-fusion protein targets the Notch signaling pathway, promoting muscle regeneration. Dr. Kaye emphasizes that this approach not only aims to address DMD but also has the potential to impact a broader range of neuromuscular conditions, thereby offering hope to a wider patient population.

In the context of accelerating drug development, MLAB's MLAB-001 stands out due to its dystrophin-mutation agnostic nature, allowing it to benefit all DMD patients, whether used alone or in conjunction with existing therapies. This adaptability signifies a paradigm shift in the treatment landscape for DMD, positioning MLAB as a key player in the biotechnology sector. As MLAB continues to assemble a world-class team of neuromuscular experts, Dr. Kaye’s appointment marks the beginning of a transformative phase for the company, strengthening its mission to deliver groundbreaking therapeutic solutions.

In addition to Dr. Kaye's appointment, MLAB Biosciences is backed by ABio-X Holding, a firm focused on advancing breakthroughs in protein therapies for musculoskeletal diseases. This support, along with investments from CBC Group, a healthcare investment firm based in Singapore, reinforces MLAB's position in the biotechnology ecosystem. The company's strategic partnerships and expert leadership pave the way for significant advancements in neuromuscular disease therapies, highlighting MLAB's potential to make a lasting impact in the field.